% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • viseslinger viseslinger Jan 2, 2013 11:16 AM Flag

    INCY at LOw of the Day - this is getting frustrating. What gives?


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Oh my god, we closed in between the low of the day and the high of the day

      What does this mean? I will not rest until I get to the bottom of it, don’t you worry viselinger

    • OMG, the stock price is going up and down and not staying exactly the same. Something must be happening. What shall we ever do?

      Chill out there, killer, I think you are the most emotional investor I’ve ever come across. And that’s saying a lot.

    • someone is buying cheap before

      In 2013, Incyte will start receiving royalties on ex-U.S. sales from its partner Novartis.

      Baricitinib is Incyte's most advanced development-stage program, partnered with Lilly (LLY). The drug is in a broad phase III campaign, focusing on RA, where phase II results demonstrated similar efficacy to that of Pfizer's recently approved Jak inhibitor (Xeljanz). Originally, Baricitinib was expected to be launched in a market with 2 established oral drugs (Pfizer's Xeljanz and AstraZeneca/Rigel's (RIGL) fostamatinib. Recent disappointing phase II data for fostamatinib imply it is not as effective as hoped and should be viewed as an incrementally positive development for Incyte.

88.98-0.29(-0.32%)Sep 23 4:00 PMEDT